Chinese biopharmaceutical company: M701 "CD3/EpCAM dual specific antibody" to release two clinical data at the 2026 ASCO meeting.

Chinese biopharmaceutical company announced that the national innovative drug M701 "CD3/EpCAM bispecific antibody" developed by its affiliated company, Sino Biopharmaceutical International Corporation, will be presented with two sets of clinical data at the 2026 annual meeting of the American Society of Clinical Oncology: Phase III registration clinical trial targeting malignant ascites and Phase II clinical trial targeting malignant pleural effusion associated with non-small cell lung cancer.